Charles River Laboratories International Inc (CRL)

Industry Diagnostics & Research

This stock can be held in an Investment Account

Sell

$176.37

Buy

$176.87

arrow-down$-5.06 (-2.79%)

Prices updated at 08 May 2026, 16:09 EDT

Prices minimum 15 mins delay

Prices in USD

Charles River Laboratories International Inc is a pharmaceutical company providing drug discovery and development services. The company provides animal models for laboratory testing, and offers manufacturing testing services to various industries.

S&P 500

0.72%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

Dr. Martin W. Mackay, PhD

CEO

Ms. Birgit Girshick

Most recent earnings

31 Dec 2025

Fiscal year end

31 Dec 2025

Employees

19,700

Head office

251 Ballardvale Street

Wilmington

United States

01887

+1 781 222-6000

askcharlesriver@crl.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Glenn G. Coleman, C.P.A. Corporate Executive Vice President and Chief Financial Officer	-
Mr. James C. Foster Director	1.55m
Dr. Martin W. Mackay, PhD Chairman of the Board	0.11m
Mr. Michael Gunnar Knell Corporate Senior Vice President and Chief Accounting Officer	0.45m
Ms. Victoria L. Creamer Corporate Executive Vice President	0.55m
Ms. Birgit Girshick Chief Executive Officer and Director	0.76m
Dr. Craig B. Thompson,M.D. Independent Director	0.09m
Ms. Virginia M. Wilson Independent Director	0.09m
Mr. Paul W. Graves Independent Director	0.09m
Mr. Mark Joseph Enyedy Independent Director	0.07m
Dr. Nancy C. Andrews, M.D.,PhD Independent Director	0.09m
Mr. Joseph W. LaPlume Corporate Executive Vice President, Corporate Development and Strategy	0.57m
Mr. George Llado, Sr Independent Director	0.07m
Mr. Steven K. Barg Independent Director	0.07m
Ms. Shannon M. Parisotto Corporate Executive Vice President	-
Ms. Reshema Kemps-Polanco Independent Director	0.09m
Mr. Abraham Ceesay Director	0.07m
Mr. Mark Mintz Corporate Executive Vice President and Chief Information Officer & Global Shared Services	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	5,887,175
BlackRock Inc	3,754,354
Fidelity Management & Research Company LLC	3,617,072
Vanguard	2,865,601
Amvescap Plc.	2,696,150

Director dealings

Date chevron-l-regular chevron-r-regular	Action
06 Nov 2025	-
22 Aug 2025	-
18 Aug 2025	-
07 Aug 2025	-
05 Jun 2025	-
02 Jun 2025	-
02 Jun 2025	-
02 Jun 2025	-
02 Jun 2025	-
02 Jun 2025	-
02 Jun 2025	-
02 Jun 2025	-
30 May 2025	-
01 Jun 2025	-
31 May 2025	-
30 May 2025	-
31 May 2025	-
30 May 2025	-
30 May 2025	-
31 May 2025	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.